6.49 USD
+0.23
3.67%
At close May 16, 4:00 PM EDT
After hours
6.50
+0.01
0.15%
1 day
3.67%
5 days
-4.42%
1 month
-15.16%
3 months
-65.20%
6 months
-72.01%
Year to date
-65.64%
1 year
-79.79%
5 years
-86.26%
10 years
-59.56%
 

About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Employees: 430

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

315% more call options, than puts

Call options by funds: $30.8M | Put options by funds: $7.41M

57% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 51

40% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 7 (+2) [Q4]

7.91% more ownership

Funds ownership: 103.54% [Q3] → 111.44% (+7.91%) [Q4]

4% less funds holding

Funds holding: 205 [Q3] → 196 (-9) [Q4]

16% less capital invested

Capital invested by funds: $1.75B [Q3] → $1.47B (-$280M) [Q4]

18% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 34

Research analyst outlook

16 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$8
23%
upside
Avg. target
$15.66
141%
upside
High target
$28
331%
upside

16 analyst ratings

10 positive
63%
neutral
38%
negative
0%
UBS
Eliana Merle
20% 1-year accuracy
4 / 20 met price target
224%upside
$21
Buy
Maintained
15 May 2025
Morgan Stanley
Terence Flynn
41% 1-year accuracy
9 / 22 met price target
69%upside
$11
Equal-Weight
Maintained
9 May 2025
Citigroup
Yigal Nochomovitz
11% 1-year accuracy
4 / 36 met price target
46%upside
$9.50
Neutral
Maintained
5 May 2025
Truist Securities
Srikripa Devarakonda
19% 1-year accuracy
6 / 32 met price target
69%upside
$11
Hold
Downgraded
5 May 2025
BMO Capital
Evan David Seigerman
12% 1-year accuracy
2 / 17 met price target
54%upside
$10
Outperform
Maintained
5 May 2025

Financial journalist opinion

Based on 58 articles about ARVN published over the past 30 days

Neutral
Accesswire
9 hours ago
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation
Neutral
Accesswire
10 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Neutral
Accesswire
1 day ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect
Neutral
Accesswire
2 days ago
ARVN ACTIVE INVESTIGATION: Lost Money on Arvinas, Inc.? Contact Levi & Korsinsky Now
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
ARVN ACTIVE INVESTIGATION: Lost Money on Arvinas, Inc.? Contact Levi & Korsinsky Now
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out
Neutral
Accesswire
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Neutral
Accesswire
3 days ago
ATTENTION ARVN SHAREHOLDERS: Investors Who Lost Money on Arvinas, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
ATTENTION ARVN SHAREHOLDERS: Investors Who Lost Money on Arvinas, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
Neutral
GlobeNewsWire
3 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Neutral
Accesswire
3 days ago
An Investigation Has Commenced on Behalf of Arvinas, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ARVN Losses.
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
An Investigation Has Commenced on Behalf of Arvinas, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ARVN Losses.
Neutral
Accesswire
3 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation
Charts implemented using Lightweight Charts™